| pubmed-article:19249411 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:19249411 | lifeskim:mentions | umls-concept:C0205127 | lld:lifeskim |
| pubmed-article:19249411 | lifeskim:mentions | umls-concept:C0948008 | lld:lifeskim |
| pubmed-article:19249411 | lifeskim:mentions | umls-concept:C1510802 | lld:lifeskim |
| pubmed-article:19249411 | lifeskim:mentions | umls-concept:C0220825 | lld:lifeskim |
| pubmed-article:19249411 | lifeskim:mentions | umls-concept:C1442488 | lld:lifeskim |
| pubmed-article:19249411 | lifeskim:mentions | umls-concept:C0034975 | lld:lifeskim |
| pubmed-article:19249411 | lifeskim:mentions | umls-concept:C0815172 | lld:lifeskim |
| pubmed-article:19249411 | lifeskim:mentions | umls-concept:C1707689 | lld:lifeskim |
| pubmed-article:19249411 | lifeskim:mentions | umls-concept:C2699007 | lld:lifeskim |
| pubmed-article:19249411 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:19249411 | pubmed:dateCreated | 2009-3-2 | lld:pubmed |
| pubmed-article:19249411 | pubmed:abstractText | Approximately one third of the 780,000 people in the United States who have a stroke each year have recurrent events. Although efficacious secondary prevention measures are available, levels of adherence to these strategies in patients who have had stroke are largely unknown. Understanding medication-taking behavior in this population is an important step to optimizing the appropriate use of proven secondary preventive therapies and reducing the risk of recurrent stroke. | lld:pubmed |
| pubmed-article:19249411 | pubmed:language | eng | lld:pubmed |
| pubmed-article:19249411 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19249411 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:19249411 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:19249411 | pubmed:month | Mar | lld:pubmed |
| pubmed-article:19249411 | pubmed:issn | 1097-6744 | lld:pubmed |
| pubmed-article:19249411 | pubmed:author | pubmed-author:ZhaoXinX | lld:pubmed |
| pubmed-article:19249411 | pubmed:author | pubmed-author:GoldsteinLarr... | lld:pubmed |
| pubmed-article:19249411 | pubmed:author | pubmed-author:PetersonEricE | lld:pubmed |
| pubmed-article:19249411 | pubmed:author | pubmed-author:Clapp-Channin... | lld:pubmed |
| pubmed-article:19249411 | pubmed:author | pubmed-author:SchwammLeeL | lld:pubmed |
| pubmed-article:19249411 | pubmed:author | pubmed-author:BushnellChery... | lld:pubmed |
| pubmed-article:19249411 | pubmed:author | pubmed-author:HardingTinaT | lld:pubmed |
| pubmed-article:19249411 | pubmed:author | pubmed-author:ZimmerLouiseL | lld:pubmed |
| pubmed-article:19249411 | pubmed:author | pubmed-author:DrewLauraL | lld:pubmed |
| pubmed-article:19249411 | pubmed:author | pubmed-author:AVAIL... | lld:pubmed |
| pubmed-article:19249411 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:19249411 | pubmed:volume | 157 | lld:pubmed |
| pubmed-article:19249411 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:19249411 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:19249411 | pubmed:pagination | 428-435.e2 | lld:pubmed |
| pubmed-article:19249411 | pubmed:meshHeading | pubmed-meshheading:19249411... | lld:pubmed |
| pubmed-article:19249411 | pubmed:meshHeading | pubmed-meshheading:19249411... | lld:pubmed |
| pubmed-article:19249411 | pubmed:meshHeading | pubmed-meshheading:19249411... | lld:pubmed |
| pubmed-article:19249411 | pubmed:meshHeading | pubmed-meshheading:19249411... | lld:pubmed |
| pubmed-article:19249411 | pubmed:meshHeading | pubmed-meshheading:19249411... | lld:pubmed |
| pubmed-article:19249411 | pubmed:meshHeading | pubmed-meshheading:19249411... | lld:pubmed |
| pubmed-article:19249411 | pubmed:meshHeading | pubmed-meshheading:19249411... | lld:pubmed |
| pubmed-article:19249411 | pubmed:meshHeading | pubmed-meshheading:19249411... | lld:pubmed |
| pubmed-article:19249411 | pubmed:meshHeading | pubmed-meshheading:19249411... | lld:pubmed |
| pubmed-article:19249411 | pubmed:meshHeading | pubmed-meshheading:19249411... | lld:pubmed |
| pubmed-article:19249411 | pubmed:meshHeading | pubmed-meshheading:19249411... | lld:pubmed |
| pubmed-article:19249411 | pubmed:meshHeading | pubmed-meshheading:19249411... | lld:pubmed |
| pubmed-article:19249411 | pubmed:meshHeading | pubmed-meshheading:19249411... | lld:pubmed |
| pubmed-article:19249411 | pubmed:meshHeading | pubmed-meshheading:19249411... | lld:pubmed |
| pubmed-article:19249411 | pubmed:meshHeading | pubmed-meshheading:19249411... | lld:pubmed |
| pubmed-article:19249411 | pubmed:meshHeading | pubmed-meshheading:19249411... | lld:pubmed |
| pubmed-article:19249411 | pubmed:meshHeading | pubmed-meshheading:19249411... | lld:pubmed |
| pubmed-article:19249411 | pubmed:year | 2009 | lld:pubmed |
| pubmed-article:19249411 | pubmed:articleTitle | The Adherence eValuation After Ischemic Stroke Longitudinal (AVAIL) registry: design, rationale, and baseline patient characteristics. | lld:pubmed |
| pubmed-article:19249411 | pubmed:affiliation | Wake Forest University Health Sciences, Winston-Salem, NC 27157, USA. cbushnel@wfubmc.edu | lld:pubmed |
| pubmed-article:19249411 | pubmed:publicationType | Journal Article | lld:pubmed |
